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During an outbreak of methanol poisonings in the
Czech Republic in 2012, we were able to study methanol
and formate elimination half-lives during intermittent
hemodialysis (IHD) and continuous veno-venous
hemodialysis/hemodiafiltration (CVVHD/HDF) and the
relative impact of dialysate and blood flow rates on
elimination. Data were obtained from 11 IHD and 13 CVVHD/
HDF patients. Serum methanol and formate concentrations
were measured by gas chromatography and an enzymatic
method. The groups were relatively comparable, but the
CVVHD/HDF group was significantly more acidotic (mean pH
6.9 vs. 7.1 IHD). The mean elimination half-life of methanol
was 3.7 and formate 1.6h with IHD, versus 8.1 and 3.6 h,
respectively, with CVVHD/HDF (both significant). The 54%
greater reduction in methanol and 56% reduction in formate
elimination half-life during IHD resulted from the higher
blood and dialysate flow rates. Increased blood and dialysate
flow on the CVVHD/HDF also increased elimination
significantly. Thus, IHD is superior to CVVHD/HDF for more
rapid methanol and formate elimination, and if CVVHD/HDF
is the only treatment available then elimination is greater
with greater blood and dialysate flow rates.
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Methanol poisoning is a medical emergency where rapid
elimination of the toxin and its metabolite is crucial for
recovery. This is because the accumulation of the toxic meta-
bolite formic acid/formate is cytotoxic through the inhibition
of mitochondrial respiration.1–4 In addition, the accumula-
tion of formic acid results in a metabolic acidosis, visual
impairment, and damage of the basal ganglia, especially when
its concentration rises to 9–11 mmol/l.5–8
The role of hemodialysis in methanol poisoning is well
established.9,10 Hemodialysis eliminates both methanol
and formate, and helps to correct metabolic acidosis. Both
intermittent and continuous modalities of hemodialysis are
commonly used in the treatment of poisonings; however,
comparative studies are scarce for methanol kinetics and
nonexistent for formate kinetics.
Given the fact that B80% of all dialysis sessions in
2006 were performed in the developed world,11 whereas
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the majority of methanol poisoning outbreaks occur in
underdeveloped countries where resources are scarce; a
thorough evaluation of the efficacy and limitations of the
various modalities of treatment should be carried out. In
addition, challenges regarding the availability of antidotes in
some countries (for example, the general lack of fomepizole
in the developing world, and cultural limitations regarding
the medicinal use of ethanol in some Islamic countries)
further emphasize the importance of extracorporeal elimina-
tion techniques in the treatment of patients with methanol
toxicity.
In addition to the availability of different dialysis equip-
ments, the choice of modality may be governed by the patient’s
clinical condition, especially with regard to the circulatory
status. The risk of performing a dialysis session with a high
dialysate and blood flow rate in a patient with a very low blood
pressure has to be weighed against the benefits of the increased
elimination rate of the toxic substances and correction of the
acidosis. We therefore also wanted to study the relative impact
of the blood and dialysate flow on the elimination of both
methanol and formate to see whether this could add to the
recommendations for the treatment.
The above questions were addressed in a prospective
observational study on methanol and formate elimination in
24 methanol-poisoned patients treated with antidotes and
two different methods of enhanced elimination in order to
compare the elimination half-lives of methanol and formate.
All patients were treated during the recent outbreak of mass
methanol poisoning in the Czech Republic in 2012, where
121 cases of poisoning were admitted and a total of 41
patients died (of whom 21 died in hospital). The epidemio-
logical description of the outbreak is presented elsewhere.12
RESULTS
The clinical features, laboratory data, and patient outcomes are
presented in Table 1. Among the 24 patients, 11 were treated
with intermittent hemodialysis (IHD), whereas 13 were treated
with a continuous modality (eight with continuous veno-
venous hemodialysis (CVVHD) and five with continuous
veno-venous hemodiafiltration (CVVHDF)). In two patients
(patients nos. 8 and 11, Table 1), ethanol infusion was started
before the initial blood sample was drawn, explaining why they
were acidotic in spite of their serum ethanol concentration.
The two groups of patients treated with different modes of
enhanced elimination were comparable by age, time to
diagnosis/treatment, and number of patients. The mean time
to diagnosis and treatment after the toxic alcohol consump-
tion was 37 h in the CVVHD/HDF group and 48 h in the IHD
group. All collected data were normally distributed with two
exceptions: (a) serum ethanol in both groups of patients, and
(b) serum methanol in the CVVHD/HDF group. There were
no statistical differences between the two groups in admis-
sion data with respect to serum methanol, formate, pCO2,
HCO3
 , base deficit, anion gap, and osmolal gap (all
P40.05). The patients treated with CVVHD/HDF were more
acidotic than those treated with IHD (mean pH 6.9±0.1 vs.
7.1±0.1, respectively), with higher lactate levels (both
P¼ 0.04).
Data on formate and methanol elimination in 11 patients
treated with IHD and 13 patients treated with CVVHD/HDF
are presented in Tables 2 and 3, respectively.
The mean methanol elimination half-life in our study
was 3.7±1.4 h for IHD and 8.1±1.2 h for CVVHD/HDF.
The mean formate elimination half-life was 1.6±0.4 h during
IHD and 3.6±1.0 h during CVVHD/HDF. The elimination
half-lives of both formate and methanol on IHD were
significantly shorter than on CVVHD/HDF (both Po0.001).
Regardless of the mode of dialysis, the elimination
half-lives of methanol (Figure 1) and formate (Figure 2)
were shorter when the blood flow rates were higher (both
Po0.001).
In the CVVHD/HDF group, the elimination half-lives
were shorter when the dialysate flow rate was higher
(P¼ 0.015, Figure 3) and when the dialyzer membrane
surface was larger (both Po0.05). In IHD, only one dialysate
flow rate and only two sizes of membrane were used
(Table 2), yet a significant correlation was found between the
dialyzer membrane surface and the elimination half-life of
methanol (P¼ 0.015, Figure 4).
No significant correlation was present between the
elimination half-lives of methanol and formate and the
predialysis serum concentrations of methanol, formate,
ethanol, bicarbonates, and lactate (all P40.05). However, a
significant correlation was present between the elimination
half-life of formate and arterial blood pH; the longer half-life
of formate was present in more acidotic patients (P¼ 0.038).
No significant correlations of methanol and formate
elimination half-lives were found with the folate substitution
(treatment with either folic or folinic acid, or without folates)
and with the specific antidote (ethanol or fomepizole)
administration (all P40.05). As regards the outcome, the
patients with visual and CNS sequelae of methanol poisoning
had significantly longer elimination half-lives of formate than
those without sequelae (P¼ 0.005). The differences in
mortality (P¼ 0.36) and morbidity (survivals with sequelae,
P¼ 0.19) between IHD and CVVHD/HDF groups were not
significant.
The results of the multivariate regression analysis of
variables influencing the elimination half-lives of formate
and methanol based on all 24 cases are shown in Tables 4
and 5. Five independent variables included in the model
explained 82.8% of the formate elimination half-life varia-
tion. The most significant factor was the blood flow rate. The
dialysate flow rate (P¼ 0.013) was based on the CVVHD/
HDF cases only; however, it was still contributing signifi-
cantly to the model. The ‘dialyzer membrane surface’ was
grouped together as interchangeable with ‘dialysate tempera-
ture’, explaining why ‘other dialyzer properties’ is given as the
term in the model, in spite of the linear correlation between
both the methanol and the formate elimination half-lives.
The variable ‘Clinical features’ consists of Glasgow coma
scale, mean arterial pressure, and pulse rate. The variable
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‘metabolic acidosis’ includes pH, pCO2, HCO3
 , base deficit,
and the anion gap (AG). The two latter variables thus reflect
the severity of the poisoning.
For the methanol elimination half-life, the model consist-
ing of four variables explained 81.5% of the variation
(Table 5). In this model, the dialysate flow rate and partially
the blood flow rate were grouped together within the discrete
factor ‘Dialyzer properties’ characterizing the mode of
hemodialysis, whereas attempting to eliminate this factor
led to the devaluation of the model. Thus, this factor
represented synthetically the difference in technical para-
meters of two modes of hemodialysis. The model for
methanol was less sensitive to the factors characterizing the
clinical state of the patient and more sensitive to the technical
parameters of hemodialysis as compared with the model for
formate. The ‘metabolic acidosis’ was the factor grouping
together pH, HCO3
 , BD, and the anion gap, reflecting the
severity of metabolic acidosis, and thus describing the
severity of poisoning in this model.
DISCUSSION
Methanol poisoning is one of the few conditions in clinical
toxicology where dialysis has an essential role.10,13 Both
methanol and formate are small molecules (molecular
weights 32 and 46 g/mol, respectively) with a volume of
distribution 0.6–0.7 l/kg for methanol14 and 0.5 l/kg for
formate,9 and no protein binding.5 Extensive toxicokinetic
data exist on the capacity of IHD to remove methanol,5,15–20
although the evidence is scarce for formate removal.9,21,22
There are no studies evaluating both the effects on methanol
and formate kinetics with continuous modes of elimination
(CVVHD/HDF) and only one that compared the efficacy of
continuous and intermittent modes of dialysis.22 In that
particular study, there were only three patients, and no
formate kinetics was determined.
The elimination of methanol without antidote therapy
is of zero order with a rate of 85 mg/l/h—that is i.e., about
half of that of ethanol.23 If methanol metabolism is blocked
by ethanol or fomepizole, methanol elimination is very slow
(elimination half-lives of about 50 h in both cases), predo-
minantly by pulmonary (and some renal) excretion.24,25 The
kinetics of methanol depends upon metabolism, and thus the
rate kinetics may vary not only depending on the amount
of toxic spirits ingested but also on the time from ingestion
to treatment, concomitant ingestion of different amounts of
ethanol in other alcoholic beverages and foods, capability
of respiratory and renal systems, as well as body weight,
muscle/adipose tissue ratio, possible folate, and protein
deficiency in chronic alcohol abusers, and other factors.
Both half-lives found during extracorporeal elimination in
our study are markedly shorter than the reported endo-
genous elimination half-life of methanol (mean 43.1–52 h)
during treatment with antidotes only.4,26 Our results further
confirm the superiority of IHD over the CVVHD/HDF
in methanol elimination from serum, supporting find-
ings from a previous study.27 Nevertheless, the circulatory
status is a concern when choosing dialysis modality in
conditions where fluid removal is necessary; this is why the
continuous modalities are often preferred for hypotensive
patients with acute kidney injury. In methanol poisoning,
however, fluid removal is usually not necessary; furthermore,
the cases with the mean arterial blood pressure lower than
70 mmHg are rare (only one patient in our study), and
therefore IHD is not expected to be riskier than CVVHD/
HDF in most cases. In fact, IHD would benefit these patients
even more because of enhanced clearance.
Table 2 | Formate and methanol kinetics in 11 patients treated on IHD
Patient
Methanol
t ½, h
R2
methanol
Formate
t ½, h
R2
formate
Observation
time
during HD, h
Blood FR,
ml/min
Dialysate
FR, ml/min
Dialyzer
type
Dialyzer
surface
area, m2
Anticoagu-
lation
Dialysate
temperature
Number
of data
points
Rebound
after HD
1 3.4 0.95 2.4 0.81 11.0 250 500 Fresenius
4008S
1.5 Hep 37.0 4 No
2 2.0 0.80 1.6 0.85 8.0 250 500 Fresenius
4008S
1.6 Hep 37.0 3 No
3 3.1 0.94 1.9 0.90 8.0 220 500 Fresenius
4008S
1.6 Hep 36.5 3 No
4 3.2 0.84 1.3 0.99 8.0 250 500 Fresenius
4008S
1.6 Hep 36.5 4 No
5 8.0 0.87 2.3 1.00 1.9 200 500 Fresenius
4008S
1.5 Hep 36.5 3 No
6 2.0 0.92 0.7 1.00 4.0 250 500 Fresenius
4008S
1.6 Hep 37.0 3 No
7 4.2 1.00 1.4 1.00 12.0 180 500 Fresenius
4008S
1.5 Hep 36.5 3 No
8 2.1 0.84 1.2 1.00 8.0 250 500 Fresenius
4008S
1.6 Hep 36.5 3 No
9 1.8 1.00 1.0 1.00 8.0 250 500 Fresenius
4008S
1.6 Hep 36.5 3 No
10 4.8 0.97 2.3 0.99 10.0 180 500 Fresenius
4008S
1.6 Hep 36.5 3 No
11 6.8 0.89 1.7 1.00 13.0 220 500 Fresenius
4008S
1.5 Hep 36.5 3 No
Mean 3.7 0.91 1.6 0.96 9.9
LCL95% 2.3 1.2 7.3
UCL95% 5.1 2.0 12.5
Abbreviations: FR, flow rate; HD, hemodialysis; Hep, heparin; IHD, intermittent hemodialysis; LCL, the lower limit of a confidence interval at the 95% level; UCL, the upper
limit of a confidence interval at the 95% level. Polysulfone dialyzer membranes have been used in all cases.
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One complication due to bleeding and one case of circuit
clotting were reported in 13 cases of treatment with CVVHD/
HDF. No complications were reported in patients treated
with IHD. No rebound was present post intermittent
hemodialysis. The rebound effect is present when the toxic
agent continues to be transferred into the arterial circulation
from peripheral body compartments, which is not the case
with methanol and formate. The other possibility of
methanol rebound is in the cases of delayed absorption of
methanol from a full stomach. In our study, the mean time to
diagnosis was 48 h in the IHD group, and thus the methanol
was completely absorbed before the onset of dialysis. The
possibility of formate rebound exists if incomplete ADH
blocking is present (due to insufficient serum ethanol levels)
and continuation of the metabolic pathway of methanol
elimination in addition to the elimination through hemo-
dialysis. In all our cases, ADH was completely blocked either
by ethanol or by fomepizole, which was proved by first-order
kinetics of methanol elimination.
In contrast to the study by Kan et al.,27 the mean methanol
elimination half-life in our study was only 54% shorter
during IHD as compared with CVVHD/HDF. The smaller
difference between the two modes of dialysis in our study can
be explained by the higher dialysate flow in the CVVHD/
HDF group. The dialysate flow rate in two patients on
CVVHDF in the cited study was 1.0 l/h only, compared with a
mean of B2.5 l/h in our study.
The results for formate elimination during IHD substan-
tially differed from the endogenous elimination half-life of
formate reported from 2.3,4 3.4,21,22,28 to 5–6 h,21,22,28 and in
two case reports 20 (ref. 29) and 77 h.30 It was also 65%
shorter than in a previous study by Kerns et al.22 during
dialysis. This study, however, possesses some weaknesses:
only six patients were dialyzed, and two of them had less than
three data points to calculate the half-life of formate (of
whom one had an extremely short half-life before initiation of
dialysis: 79 min). Further, there was variability in the blood
flow in two patients (out of five) during dialysis, which
means that half-life cannot be calculated. Our results better
correspond with those of Hantson et al.21, who calculated the
mean formate elimination half-life during hemodialysis in 18
patients to be 1.81±0.78 h, which was statistically different
from the values observed without dialysis. Furthermore, the
formate elimination half-life before or in the absence of
dialysis calculated in the cited study (6.1±3.3 h) was
substantially longer than in the former studies based on
fewer cases.
The mean elimination half-life of formate on IHD in
our study was 56% shorter as compared with CVVHD/HDF
(1.6 vs. 3.6 h, Po0.001) and significantly shorter than
the endogenous half-lives calculated in the studies of Kerns
et al.22 and Hantson et al.21 Our results suggest that the
shorter mean elimination half-life of formate and methanol
results from the higher rates of blood flow and dialysate
flow. The correlations between the blood flow and the
elimination half-lives of methanol and formate were linearT
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(Figures 1 and 2), with elimination half-lives decreasing with
increasing blood flow (Po0.001). Blood flow rate was the
most significant factor in the multivariate model for formate
and one of the most significant factors in the model for
methanol. In CVVHD/HDF, the elimination half-lives were
shorter when the dialysate flow rate was higher and the
dialyzer membrane surface was larger. The elimination half-
life of formate in two patients treated with the highest
dialysate flow rate possible on CVVHD (4.8 l/h) was
significantly shorter (mean 2.2 h) as compared with the
mean for this group (3.6±1.0 h; Po0.05). On the basis of
these findings, the blood flow and the dialysate flow when
using continuous dialysis should be increased as much as
possible, taking the patientˇs condition into account. Depend-
ing on the local dialysis equipment (citrate or heparin
anticoagulation), this should be performed under a close
evaluation of the acid–base and electrolyte status of the
patient.
We did not find any correlation between administration of
folates and formate elimination half-lives, supporting the
findings by Sanaei-Zadeh et al.31 The difference in formate
elimination half-lives between the patients with and without
folic or folinic acid administration was not statistically
significant. In addition, hemodialysis enhances the formate
elimination to such an extent that the effect of the slower
pathway of tetrahydrofolate-mediated formate conversion is
less apparent. However, further studies are necessary to
evaluate this assumption.
Recommendations on the length of dialysis in methanol
poisoning often focus on serum methanol, if available.
Analyses of the toxic compound formic acid are less
available,32 and therefore surrogate markers such as the
degree of metabolic acidosis (base deficit) and the anion gap
are used.2 In severe methanol poisoning, it is the removal of
toxic formate by dialysis and the correction of metabolic
acidosis that is crucial, and the lowering of serum methanol is
the secondary task if ADH is blocked adequately by ethanol
or fomepizole. These facts may explain the clinical experience
that B8 h of IHD are usually sufficient even in severe
methanol poisoning, provided that the metabolic acidosis is
corrected, ADH is blocked, and formate is eliminated
(normalized anion gap).
In mass methanol outbreaks with a large number of
patients, if the dialysis capacities are limited, we recommend
a minimum of 8 h of IHD and 18 h of CVVHD/HDF before
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Figure 1 | Elimination half-life of methanol versus blood flow rate
(y¼  0.04xþ 13.9, R2¼ 0.52).
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Figure 2 | Elimination half-life of formate versus blood flow rate
(y¼  0.02xþ 6.5, R2¼ 0.44).
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Figure 3 | Elimination half-life of methanol versus dialysate flow
rate on CVVHD/HDF (y¼  0.0011xþ 10.91, R2¼ 0.12).
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Figure 4 | Elimination half-life of methanol versus dialyzer
membrane surface (y¼  5.49xþ 17.37, R2¼ 0.44).
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discontinuation of the dialysis, if the methanol concentration
or the osmolal gap cannot be measured. This would
theoretically eliminate all formate (5 T½¼ 8 and 18 h,
respectively), as well as a sufficient amount (80%) of the
methanol. The continued antidote treatment for at least
12–24 h after the discontinuation of the dialysis, as well as
having the possibility of early discovery of any signs of
potential rebound acidosis, makes this a clinically and
scientifically sound approach.
A similar toxicokinetic approach toward methanol elimi-
nation (5 T½ to remove 100%) would, based on our data,
give an estimated need for 18 h of IHD and 40 h of CVVHD/
HDF. Assuming that 3 T½ (12.5% of original serum
methanol is remaining) is sufficient (all patients should have
antidote treatment for at least 12–24 h post dialysis), it would
still require 11 h of IHD and 24 h of CVVHD/HDF,
respectively. The problem with this way of guiding the length
of dialysis is that one is not addressing the elimination of the
(real) toxic agent.
Our study supports the superiority of IHD over CVVHD/
HDF in terms of the rate of elimination of both methanol
and formate, the latter being especially important in the late-
presenting patients. On the basis of the apparent increased
elimination with the higher blood and dialysate flow, we
recommend optimizing dialysis by increasing the blood flow
rate on IHD and the blood and dialysate flow rate on
CVVHD/HDF as much as possible, given the limitations of
the apparatus and the patient condition. Further studies with
more cases are necessary to demonstrate whether the mode
of hemodialysis also affects the mortality and long-term
visual/CNS sequelae in methanol-poisoned patients; however,
our data suggest at least a correlation between the rate
of formate elimination and health sequelae of methanol
poisoning: the patients with health sequelae had significantly
longer elimination half-lives of formate than those without
sequelae (P¼ 0.005).
Strength and limitations
The limitations of this study can be attributed to certain
confounders: possible variations in the time, amount, and
patterns of toxic liquor intake, individual differences in
the methanol and formate metabolism, and the available
modalities for treatment (other than the modality of
enhanced elimination) can add to the limitations. However,
the two groups of patients treated with different modes of
enhanced elimination were comparable by age, latency
period, and size; most of the collected data exhibited normal
distribution; for all practical means, there were no statistical
differences in admission laboratory data and statistical
deviations between both groups. There were limited numbers
of data points for most calculations among the IHD patients
(predominantly three data points); however, the observation
time was sufficiently long, and the correlation on the
semilogarithmic plot was good.
This study was not designed as a randomized controlled
trial because the choice of the method of enhanced
elimination in each case was based on clinical practice at
individual sites, as appropriate, and conditioned by different
factors, giving the possibility of inherent bias. Nevertheless,
this study was not conceived as a study looking at defining
Table 4 | The multivariate regression analysis of formate elimination half-life (R2¼ 0.828)
95% Confidence interval
Parameter Regression coefficient Standard error t-stat. P-value LB UB Partial Eta squared
Intercept  39.96 8.305  4.811 o0.001  57.41  22.51 56.3%
Blood flow rate  0.022 0.004  5.467 o0.001  0.03  0.014 62.4%
Dialysate flow rate  0.0004 0.0001  2.759 0.013  0.001 0.0001 29.7%
Other dialyzer properties 1.328 0.234 5.678 o0.001 0.836 1.819 64.2%
Clinical features  0.026 0.008  3.388 0.003  0.042  0.010 38.9%
Metabolic acidosis 0.331 0.111 2.989 0.008 0.098 0.563 33.2%
Abbreviations: LB, lower bound of a confidence interval at the 95% level of confidence; UB, upper bound of a confidence interval at the 95% level of confidence.
‘Other dialyzer properties’ include dialyzer membrane surface and dialysate temperature. ‘Clinical features’ include Glasgow coma scale (GCS), mean arterial pressure (MAP),
and pulse rate. ‘Metabolic acidosis’ includes pH, pCO2, HCO3
 , base deficit (BD), and the anion gap (AG).
Table 5 | The multivariate regression analysis of methanol elimination half-life (R2¼ 0.815)
95% Confidence interval
Parameter Regression coefficient Standard error t-stat. P-value LB UB Partial Eta squared
Intercept 15.761 3.325 4.740 o0.001 8.802 22.72 54.2%
Dialyzer properties 4.218 0.889 4.746 o0.001 2.358 6.079 54.2%
Blood flow rate  0.018 0.008  2.219 0.039  0.035  0.001 20.6%
Dialyzer surface  5.95 1.660  3.584 0.002  9.425  2.475 40.3%
Metabolic acidosis  0.092 0.032  2.863 0.010  0.160  0.025 30.1%
Abbreviations: BD, base deficit; LB, lower bound of a confidence interval at the 95% level of confidence; UB, upper bound of a confidence interval at the 95% level of
confidence.
‘Metabolic acidosis’ includes pH, pCO2, HCO3
 , BD, and the anion gap (AG).
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the best modality in terms of outcome, rather describing the
differences in methanol and formate elimination half-lives
only, which should not be biased by the above selection of the
groups.
MATERIALS AND METHODS
Patients and treatment
The study design was a prospective, observational—uncontrolled
with respect to the hemodialysis modality selection, types of
antidotes, and other treatments administered—study. Patients were
eligible if they were not pregnant, 418 years of age, and met the
following criteria: confirmed methanol poisoning (serum methanol
46.3 mmol/l), documented circumstances of methanol ingestion
and time to diagnosis, and sufficient laboratory data, including
serum methanol and formate level on admission and at the
initiation of hemodialysis.
Twenty-four methanol-poisoned patients were treated in 10
hospitals between September and December 2012. The patients were
treated with alkalization, ethanol or fomepizole, or a combination of
both antidotes (for example, start of therapy with fomepizole
followed by ethanol administration). Folates (folic or folinic acid)
were given to 17/24 patients according to the standard protocols.
Patient nos 1–11 were treated with IHD, and patient nos 12–24
were treated with continuous methods of enhanced elimination
(nos 12–19 with CVVHD and nos 20–24 with CVVHDF). Most of
the patients treated with IHD (9/11 patients) were admitted to the
intensive care units of internal medicine departments, and the
patients treated with CVVHD/HDF were predominantly admitted
to the departments of anesthesiology and resuscitation (12/13
patients).
Patients underwent hemodialysis if they exhibited any of the
following: serum methanol higher than 15.8 mmol/l, acidemia, or
visual toxicity. The choice of the method of enhanced elimination in
each case was based on several factors, such as the hemodynamic
stability of the patient on admission (all the patients treated with
IHD had mean arterial pressure 470 mm Hg, 4/13 patients treated
with CVVHD had mean arterial pressurep70 mm Hg), and severity
of clinical symptoms of poisoning (8/13 patients treated with
CVVHD were comatose on admission (GCSo8), whereas only 2/11
treated with IHD. Another significant factor was the type of dialyz-
ing equipment available in a medical facility: Some smaller hospitals
had the dialyzing equipment in the anesthesiology departments
only, making only the continuous mode of hemodialysis available.
The larger hospitals usually had IHD equipment available.
As for the antidotes, ethanol was given to seven patients treated
with IHD and nine patients were treated with CVVHD/HDF,
whereas fomepizole (alone or followed by ethanol administration)
was administered to four patients in each group. Six patients treated
with IHD and 11 patients treated with CVVHD/HDF received
folates. IHD was initiated 2 h after admission to the hospital (range
1–2 h). It was performed for a median duration of 8 h. CVVHD/
HDF was started 3.5 h after admission to the hospital (range
0.5–12 h) and lasted for a median duration of 44 h.
Laboratory investigations
Venous blood for methanol and formate analysis was obtained on
admission, at the start of hemodialysis, every 2–4 h during the
dialysis session, and at the end of dialysis. The blood samples for the
osmolality measurements were not necessarily taken at the same
time as the samples taken for the methanol and formate analysis in
this study, and correlation studies between osmolality and methanol
could not be performed. Nonetheless, the first available osmolality
was presented. The stated parameters of CVVHD/HDF were
maintained during the observation time. In most cases, the duration
of CVVHD/HDF was longer than the observation time; however, it
was not practical for the study purpose and ethical issues to
continue blood sampling. Blood samples were spun, serum was
separated, and it was frozen until analyses. Methanol was measured
by a gas chromatographic method with flame ionization detection
and a direct injection with internal standard (Gas Chromatograph
Chrom 5, Laboratory Instruments Prague, Czech Republic), limit of
detection 1.9 mmol/l, and day-to-day coefficient of variation
2.5–5.4%. Calibrators and controls were made by dilution of
methanol p.a. (Penta, Czech Republic).
Formate was measured enzymatically on a Hitachi analyzer
(Hitachi 912, Hitachi Science Systems, Tokyo, Japan) using formate
dehydrogenase (Roche, Meylan, France) and NAD (Roche), accord-
ing to a previously published method.32–35 Pure sodium formate
(Sigma-Aldrich, St Louis, MO) was used to prepare a standard of
1.1 mmol/l phosphate buffer and two control sera. Day-to-day
coefficient of variation was 5.6%, and the upper reference limit was
4 mmol/l.
Serum ethanol was analyzed by gas chromatography with flame
ionization detection and a direct injection with internal standard
(Gas Chromatograph Chrom 5, Laboratory Instruments). The limit
of detection was 0.9 mmol/l, and the day-to-day coefficient of
variation was 3.8–7.1%. Ethanol standards were purchased (Erba
Lachema, Brno, Czech Republic). Osmolality was measured by
freezing point depression method on a Fiske one-ten osmometer.
The reference range for the osmolal gap was  9–19 mOsm per kg
H2O. The osmolal contribution from ethanol (two patients) was
subtracted from the measured osmolality.
Calculations and data analysis
Elimination half-life was calculated from the relationship of
methanol and formate versus time: linear regression analysis
determined the elimination constant (Ke), from the slope of the
natural logarithm of methanol or formate versus time.36 The ‘first-
order’ intradialytic elimination half-life was then calculated from the
relationship t1/2¼ 0.693/Ke.
The AG and the osmolal gap were calculated by using the
following formulae:
AG¼ (Naþ þKþ )  (HCO3 þCl ), and OG¼MO 
(1.86Naþ þ glucoseþ urea)/0.93, where MO represents the
measured osmolality.37
Data are expressed as means with confidence interval (signifi-
cance level a¼ 0.05). The elimination half-lives were compared
using the unpaired t-test. Pearson correlation analysis was
performed for characterization of logarithmic dependence concen-
tration of methanol and formate on time, respectively.
Median, modus, arithmetic mean, and confidence intervals were
applied for the calculation of average values of different groups of
patients. The normality of data was verified using tests based on
sample skewness and kurtosis; the normality of one sample was
based on the Kolmogorov–Smirnov test. We used the independent
t-tests for comparison of independent parameters between two
groups of patients, and the multivariate regression models (forward,
backward, and stepwise methods) for the determination of
optimal sets of explanatory variables for the methanol and formate
elimination half-lives. We have used also the exploratory factor
206 Kidney International (2014) 86, 199–207
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analysis on Pearson correlations among the monitored input
variables as an auxiliary tool of explanatory regression models.
Statistical documentation was performed in Excel (Microsoft,
Redmond, WA), and the formal calculations were produced in QC
Expert software 3.1 (Trilobyte, Pardubice, Czech Republic) and in
IBM SPSS ver. 17.0 and Statistica SF ver. 10.0 (both licensed to First
Faculty of Medicine of the Charles University in Prague).
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